Every Form 4 that Monopar Therapeutics Inc. (MNPR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow MNPR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNPR filings page.
Monopar Therapeutics (MNPR) director Kim R. Tsuchimoto reported an amended set of transactions on August 26, 2026, correcting a prior Form 4. The director exercised stock options for 2,055 shares at an exercise price of $30.00 and 2,035 shares at $14.00, receiving an equal number of common shares. On the same date, a total of 4,090 common shares were sold in multiple trades at weighted average prices between $108.83 and $113.84 per share, with underlying trade ranges from $108.07 to $114.34. All option exercises and sales were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026. Following these transactions, 11,486 shares are reported as held indirectly by the Kim R. Tsuchimoto Trust dated October 6, 2015.
Monopar Therapeutics (MNPR) director Raymond Anderson amended a prior insider report to include previously omitted option exercises and to reflect Monopar’s 5-for-1 reverse stock split effective August 12, 2024. On August 25, 2026, he exercised options for 3,142 shares of common stock at a $30.00 exercise price and sold 3,142 shares in three open-market transactions at weighted average prices of $110.04, $111.07, and $113.05. All transactions were effected under a Rule 10b5-1 trading plan executed on May 26, 2026.
Monopar Therapeutics (MNPR) reported that Acting Chief Medical Officer Patrice Rioux exercised 1,380 Stock Options for Common Stock on 2026-08-26 at an exercise price of $0.005 per share, converting them into 1,380 Common Shares. On the same date, 1 Common Share was sold at $111.26 per share. The option exercise exhausted this particular option grant, leaving 0 derivative shares reported as remaining from it. These transactions were effected pursuant to a Rule 10b5-1 Plan executed by the reporting person on May 27, 2026.
Monopar Therapeutics (MNPR) director Tsuchimoto Kim R reported multiple open-market sales of common stock. On August 26, 2026, the reporting person sold a total of 4,090 shares of Monopar common stock in six transactions, each reported at a weighted average price between $108.83 and $113.84 per share. The trades were effected pursuant to a Rule 10b5-1 Plan executed on May 27, 2026, and each sale was executed through multiple trades within disclosed price ranges.
Monopar Therapeutics (MNPR) director Raymond Anderson reported selling a total of 3,142 shares of common stock on August 25, 2026 in three open-market transactions under a Rule 10b5-1 trading plan executed on May 26, 2026. The reported per-share prices are weighted averages for shares sold across disclosed price ranges.
Monopar Therapeutics’ Chief Financial Officer Vu Quan Anh reported routine equity compensation activity tied to restricted stock units. On the vesting date, 1,228 restricted stock units converted into the same number of common shares. The company withheld 507 shares to cover tax obligations, a non‑market disposition.
Following these transactions, Vu Quan Anh directly holds 2,221 shares of common stock. He also retains 8,598 unvested restricted stock units from a 9,826-unit grant awarded on December 2, 2025, which began vesting on June 30, 2026 and is scheduled to fully vest by December 31, 2029.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported compensation-related stock activity. On June 30, 2026, 12,873 restricted stock units vested and settled into the same number of common shares. The issuer withheld 4,084 shares at $92.59 per share to cover applicable tax obligations.
Following these transactions, Robinson holds 99,267 shares of Monopar common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. The filing reflects routine RSU vesting and associated tax-withholding dispositions, not open-market purchases or sales.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine exercised and settled 5,254 restricted stock units on June 30, 2026, receiving 5,254 shares of common stock. 2,309 shares were withheld by the company at $92.59 per share to cover withholding taxes. Following these transactions, he directly owns 55,614 shares of Monopar common stock. The restricted stock units come from multi-year grants that vest in quarterly installments through December 2029.
Monopar Therapeutics director Nicole Sweeny received a grant of stock options, acquiring rights to 1,284 shares of common stock. The options have an exercise price of $87.68 per share and expire on June 26, 2036.
The grant vests in two equal installments, with 50% vesting on September 30, 2026 and the remaining 50% vesting on December 31, 2026. Following this grant, Sweeny holds options on 1,284 shares directly. This is a compensation-related award rather than an open-market stock purchase or sale.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported routine equity compensation activity. On March 31, 2026, 6,732 restricted stock units vested and were settled into an equal number of common shares at an exercise price of $0.00 per share.
Of these shares, 1,972 were withheld by the issuer at $54.79 per share to cover applicable tax withholding obligations. Following these transactions, Robinson held 90,478 shares of common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.
Monopar Therapeutics Chief Operating Officer Andrew Cittadine increased his direct equity stake through RSU vesting. On March 31, 2026, 3,514 restricted stock units vested and were settled into an equal number of common shares at a conversion price of $0.00 per share.
To cover withholding taxes on this vesting, 1,571 common shares were withheld by the company at a value of $54.79 per share, rather than sold in the open market. After these transactions, Cittadine directly owned 52,669 shares of Monopar Therapeutics common stock.
Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.
Monopar Therapeutics granted Chief Clinical Science Officer Susan Rodriguez stock options covering 48,728 shares on March 2, 2026. The options were reported at a price of $0.0000 per share and are held directly.
According to the vesting terms, 6/48ths of the options vest on September 2, 2026, with the remaining 1/48th vesting each month thereafter. After this grant, Rodriguez was reported as holding 48,728 stock options in total.
Monopar Therapeutics Chief Executive Officer and director Chandler Robinson reported an indirect acquisition of 62,815 shares of common stock on a Form 4. The shares were received at $0 per share through a pro rata liquidating distribution from Tactic Pharma, LLC and are held by the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020. Following this transaction, Robinson also reports 85,718 common shares held directly.
Monopar Therapeutics director reports indirect share distribution. A reporting person who serves as a director of Monopar Therapeutics disclosed an indirect disposition of 43,499 shares of common stock on 12/16/2025 at a stated price of $0 per share, coded as transaction type "J" (other). The filing explains this relates to a pro rata distribution of Monopar shares by Gem Pharmaceuticals, LLC to its members, in which the reporting person states they have no pecuniary interest.
After the transaction, the reporting person reports 567,580 Monopar shares held indirectly through Gem and 93,750 shares held by DMH Business LLC. As a manager of Gem and of DMH Business LLC’s controlling owner, the reporting person may be deemed to share voting and dispositive power over these shares but disclaims beneficial ownership except to the extent of any pecuniary interest.
Monopar Therapeutics director reported receiving additional company shares in an insider transaction. On 12/16/2025, the reporting person acquired 7,710 shares of Monopar Therapeutics common stock at a stated price of $0, coded as transaction type J. After this transaction, the reporting person beneficially owned 13,883 shares, held directly.
According to the explanation provided, the shares were received through a pro rata distribution from Gem Pharmaceuticals, LLC, in which the reporting person is a non-managing member. The filing indicates it was submitted for one reporting person in their capacity as a director of Monopar Therapeutics.
Monopar Therapeutics (MNPR) insider filing: Andrew Cittadine, the company's Chief Operating Officer and a director, reported equity activity dated 09/30/2025. He received 4,327 shares upon vesting and settlement of restricted stock units. To satisfy tax withholding on the vesting, 1,896 shares were surrendered at an indicated price of $81.67 per share.
After these transactions the filing shows beneficial ownership figures reported on the form: 50,185 shares following the acquisition line and 48,289 shares following the withholding line; the form also lists 38,674 restricted stock units/RSU-related shares held following the reported transactions. The form is executed by attorney-in-fact Quan Vu on 10/02/2025.
Monopar Therapeutics (MNPR) director and CEO Dr. Robinson Chandler reported insider transactions on Form 4 showing restricted stock unit vesting and resulting share movements on 09/30/2025. He received 8,726 shares upon vesting and settlement of RSUs and had 2,646 shares withheld to satisfy withholding taxes, leaving 82,198 shares reported as directly owned after the transactions. The filing also discloses 272,026 shares held by Tactic Pharma LLC, over which Dr. Robinson may be deemed to share voting and dispositive power; he expressly disclaims beneficial ownership of those shares except to the extent of his pecuniary interest. Transactions are tied to multiple RSU grants made in 2022, 2023 and 2025 with scheduled vesting through December 31, 2028.